# Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis

> **NCT04211363** · PHASE3 · COMPLETED · sponsor: **Arcutis Biotherapeutics, Inc.** · enrollment: 439 (actual)

## Conditions studied

- Chronic Plaque Psoriasis

## Interventions

- **DRUG:** Roflumilast 0.3% cream
- **DRUG:** Vehicle Cream

## Key facts

- **NCT ID:** NCT04211363
- **Lead sponsor:** Arcutis Biotherapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-20
- **Primary completion:** 2020-11-16
- **Final completion:** 2020-11-16
- **Target enrollment:** 439 (ACTUAL)
- **Last updated:** 2022-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04211363

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04211363, "Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04211363. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*